Participant completion of longitudinal assessments in an online cognitive aging registry: The role of medical conditions.

This study aimed to understand whether older adults' longitudinal completion of assessments in an online Alzheimer's disease and related dementias (ADRD)-related registry is influenced by self-reported medical conditions. Brain Health Registry (BHR) is an online cognitive aging and ADRD-related research registry that includes longitudinal health and cognitive assessments. Using logistic regressions, we examined associations between longitudinal registry completion outcomes and self-reported (1) number of medical conditions and (2) eight defined medical condition groups (cardiovascular, metabolic, immune system, ADRD, current psychiatric, substance use/abuse, acquired, other specified conditions) in adults aged 55+ ( We found that the likelihood of longitudinally completing the initial questionnaire was negatively associated with reporting a diagnosis of ADRD and current psychiatric conditions but was positively associated with reporting substance use/abuse and acquired medical conditions. The likelihood of longitudinally completing the cognitive assessment task was negatively associated with number of reported medical conditions, as well as with reporting cardiovascular conditions, ADRD, and current psychiatric conditions. Previously identified associations between ethnocultural identity and longitudinal assessment completion in BHR remained after accounting for the presence of medical conditions. This post hoc analysis provides novel, initial evidence that older adults' completion of longitudinal assessments in an online registry is associated with the number and types of participant-reported medical conditions. Our findings can inform future efforts to make online studies with longitudinal health and cognitive assessments more usable for older adults with medical conditions. The results need to be interpreted with caution due to selection biases, and the under-inclusion of minoritized communities.

Informations de copyright

© 2024 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Déclaration de conflit d'intérêts

Chengshi Jin, Anna Aaronson, Joseph Eichenbaum, Adam Diaz, Rachana Tank, Monica Camacho, Derek Flenniken, Juliet Fockler, Diana Truran‐Sacrey, and Aaron Ulbricht report no potential conflict of interest. Miriam Ashford receives support from the National Institutes of Health's (NIH) National Institute on Aging (NIA), grant F32AG072730‐01 (made to institution) and declares no potential conflicts of interest. John Neuhaus declares to have grant funding from the NIH.R. Scott Mackin declares to have grants from the following entities: NIH and Janssen Research and Development LLC, with all grant payments made to university. Michael W. Weiner receives support for his work from the following funding sources: NIH, grants from Department of Defense (DOD), grants from Patient‐Centered Outcomes Research Institute (PCORI), grants from California Department of Public Health (CDPH), grants from University of Michigan, grants from Siemens, grants from Biogen, grants from Hillblom Foundation, grants from the Alzheimer's Association, grants from the state of California, grants from Johnson & Johnson, grants from Kevin and Connie Shanahan, grants from GE, grants from VUmc, grants from Australian Catholic University (HBI‐BHR), grants from The Stroke Foundation, grants from the Veterans Administration, personal fees from Acumen Pharmaceutical, personal fees from Cerecin, personal fees from Dolby Family Ventures, personal fees from Eli Lilly, personal fees from Merck Sharp & Dohme Corp., personal fees from the NIA, personal fees from Nestle/Nestec, personal fees from PCORI/PPRN, personal fees from Roche, personal fees from University of Southern California (USC), personal fees from NervGen, personal fees from Baird Equity Capital, personal fees from BioClinica, personal fees from Cytox, personal fees from Duke University, personal fees from Eisai, personal fees from FUJIFILM‐Toyama Chemical (Japan), personal fees from Garfield Weston, personal fees from Genentech, personal fees from Guidepoint Global, personal fees from Indiana University, personal fees from Japanese Organization for Medical Device Development, Inc. (JOMDD), personal fees from Medscape, personal fees from Peerview Internal Medicine, personal fees from Roche, personal fees from T3D Therapeutics, personal fees from WebMD, personal fees from Vida Ventures, personal fees from The Buck Institute for Research on Aging, personal fees from China Association for Alzheimer's Disease (CAAD), personal fees from Japan Society for Dementia Research, personal fees from Korean Dementia Society, outside the submitted work; and I hold stocks or options with Alzheon Inc., Alzeca, and Anven. Monica Rivera Mindt declares to have grants from the following entities (NIH/NIA 2U19AG024904‐16, NIH/NIA R01AG065110‐01A1, NIH/NIA #R56AG075744, NIH/NIA R01AG066471‐01A1, NIH/NIA #U19AG078109‐01), with all grant payments made to university. Rachel L Nosheny has received support from NIA (support to institution) for the present manuscript and grants from NIA (grant to institution), California Department of Public Health (grant to institution) Genentech, Inc., Health Equity Innovations Fund (grant to institution), Alzheimer's Association (grant to institution), and Genentech Charitable Foundation (grant to institution). Author disclosures are available in the supporting information.